Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma

This study was supported by The Japan Society for the Promotion of Science (JSPS) (grant no: JP19K176974) KAKENHI Early-Career Scientists (K Kunimasa), Takeda Science Foundation (K Kunimasa) and Osaka International Cancer Institute (K Kunimasa, H Tahara). H Kawachi reports personal fee from Chugai Pharmaceutical Co outside the submitted work; K Kunimasa reports personal fees from Novartis Pharma and Chugai Pharmaceutical Co outside the submitted work; M Tamiya reports personal fees from Chugai Pharmaceutical, personal fees from AstraZeneca, personal fees from Pfizer Japan Inc., personal fees from Boehringer-Ingelheim, outside the submitted work; K Nishino reports personal fees from Boehringer Ingelheim, personal fees from Chugai Pharma, personal fees from AstraZeneca, personal fees from MSD, outside the submitted work; T Kumagai reports grants and personal fees from Ono Pharmaceutical, grants and personal fees from MSD, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from AstraZeneca, grants from Takeda Pharmaceutical Companiy, personal fees from Taiho Pharmaceutical Co, personal fees from Merck Serono Co, grants and personal fees from Pfizer Japan Inc., personal fees from Novartis Pharma, personal fees from Eli Lilly Japan. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

留言 (0)

沒有登入
gif